Supporting information for Ide et al. (2002) Proc. Natl. Acad. Sci. USA, 10.1073/pnas.222537099
Fig. 13.
Detection of activated CSF-1R in bone and liver metastatic sites. These stainings were based on the EnVision+ System (DAKO) for polyclonal rabbit anti-human CSF-1R antibody (Santa Cruz Biotechnology, lot K130) or combined with the tyramide system for polyclonal antibody raised against the phosphorylated tyrosine 723 peptide (PY723) of CSF-1R. The majority of the samples showed uniform staining of constant intensity, ranging from moderate to strong, in malignant epithelial tumor cells. The tumor areas displayed staining for the CSF-1R and the PY723 modification of CSF-1R, which was blocked by the cognate peptide. The very dark staining in the bone panel is over an area of demineralized bone tissue.